These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 8402512)

  • 21. Robbing peter to pay paul: financing clinical trial follow-up.
    Dilts DM
    J Clin Oncol; 2012 May; 30(13):1404-5. PubMed ID: 22454422
    [No Abstract]   [Full Text] [Related]  

  • 22. Estimating per patient funding for cancer clinical trials: an Ontario based survey.
    Wright JR; Roche K; Smuck B; Cormier J; Cecchetto S; Akow M; Pilatzke S; Pritchard KI
    Contemp Clin Trials; 2005 Aug; 26(4):421-9. PubMed ID: 15925548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient care cancer clinical trials at the National Cancer Institute: a resource for payers and providers.
    Pearson D
    Manag Care Q; 2002; 10(1):33-7. PubMed ID: 15988953
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Variation in approval by insurance companies of coverage for autologous bone marrow transplantation for breast cancer.
    Peters WP; Rogers MC
    N Engl J Med; 1994 Feb; 330(7):473-7. PubMed ID: 8289855
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The financial impact of investigational drug services.
    Rogers SD; Lampasona V; Buchanan EC
    Top Hosp Pharm Manage; 1994 Apr; 14(1):60-6. PubMed ID: 10133561
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Time-Trend Economic Analysis of Cancer Drug Trials.
    Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
    Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Code of ethics for the University of Texas System Cancer Center M.D. Anderson Hospital and Tumor Institute.
    van Eys J; Bowen JM; Alt J; Kolenda BJ; Martin RS; Reiser SJ; Shullenberger CC; von Eschenbach AC
    Tex Med; 1985 Jun; 81(6):41-3. PubMed ID: 4012651
    [No Abstract]   [Full Text] [Related]  

  • 28. Using a public hospital funding model to strengthen a case for improved nutritional care in a cancer setting.
    Boltong AG; Loeliger JM; Steer BL
    Aust Health Rev; 2013 Jun; 37(3):286-90. PubMed ID: 23731960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incremental costs of enrolling cancer patients in clinical trials: a population-based study.
    Wagner JL; Alberts SR; Sloan JA; Cha S; Killian J; O'Connell MJ; Van Grevenhof P; Lindman J; Chute CG
    J Natl Cancer Inst; 1999 May; 91(10):847-53. PubMed ID: 10340904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer patient care in clinical trials sponsored by the National Cancer Institute: what does it cost?
    Brown ML
    J Natl Cancer Inst; 1999 May; 91(10):818-9. PubMed ID: 10340896
    [No Abstract]   [Full Text] [Related]  

  • 32. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Free-riding and the prisoner's dilemma: problems in funding economic analyses of phase III cancer clinical trials.
    Bennett CL; Smith TJ; George SL; Hillner BE; Fleishman S; Niell HB
    J Clin Oncol; 1995 Sep; 13(9):2457-63. PubMed ID: 7545222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reimbursement issues in clinical oncology.
    Vogelzang NJ; Chabner BA; Periman P; Ohrt DK; McCann BC; Burns JM; Bayer R
    Semin Oncol; 1988 Dec; 15(6 Suppl 6):34-43. PubMed ID: 3061015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Creating a code of ethics: report of the University of Texas System Cancer Center M.D. Anderson Hospital and Tumor Institute.
    van Eys J; Bowen JM; Alt J; Kolenda BJ; Martin RS; Reiser SJ; Shullenberger CC; von Eschenbach AC
    CA Cancer J Clin; 1986; 36(2):115-9. PubMed ID: 3082482
    [No Abstract]   [Full Text] [Related]  

  • 36. The impact of clinical pathways on the practice of head and neck oncologic surgery: the University of Texas M. D. Anderson Cancer Center Experience.
    Chen AY; Callender D; Mansyur C; Reyna KM; Limitone E; Goepfert H
    Arch Otolaryngol Head Neck Surg; 2000 Mar; 126(3):322-6. PubMed ID: 10722004
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical cancer research, DNR orders, and medical economics: a complex interrelationship.
    Markman M
    Cancer Invest; 1987; 5(3):237-9. PubMed ID: 3115500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The crisis in clinical cancer research. Third-party insurance and investigational therapy.
    Antman K; Schnipper LE; Frei E
    N Engl J Med; 1988 Jul; 319(1):46-8. PubMed ID: 3288868
    [No Abstract]   [Full Text] [Related]  

  • 39. The project data sphere initiative: accelerating cancer research by sharing data.
    Green AK; Reeder-Hayes KE; Corty RW; Basch E; Milowsky MI; Dusetzina SB; Bennett AV; Wood WA
    Oncologist; 2015 May; 20(5):464-e20. PubMed ID: 25876994
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical trials: are they a good buy?
    Bennett CL; Adams JR; Knox KS; Kelahan AM; Silver SM; Bailes JS
    J Clin Oncol; 2001 Dec; 19(23):4330-9. PubMed ID: 11731516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.